Article

Effect of Homocysteine-Lowering B Vitamin Treatment on Angiographic Progression of Coronary Artery Disease: A Western Norway B Vitamin Intervention Trial (WENBIT) Substudy

Institute of Medicine, University of Bergen, Bergen, Norway.
The American journal of cardiology (Impact Factor: 3.43). 06/2010; 105(11):1577-84. DOI: 10.1016/j.amjcard.2010.01.019
Source: PubMed

ABSTRACT Total plasma homocysteine (tHcy) is an independent risk factor for coronary artery disease, and tHcy is lowered by B vitamins. To assess the effect of homocysteine-lowering B-vitamin treatment on angiographic progression of coronary artery disease, this substudy of the Western Norway B Vitamin Intervention Trial (WENBIT) included patients who had undergone percutaneous coronary intervention. The patients were randomized to daily oral treatment with folic acid, vitamin B(12), and vitamin B(6) or placebo in a 2 x 2 factorial design. The coronary angiograms obtained at baseline and follow-up were evaluated. The primary angiographic end points were the changes in minimum lumen diameter and diameter stenosis. A total of 348 subjects (288 men) with a mean +/- SD age of 60 +/- 10.2 years were followed up for a median of 10.5 months (twenty-fifth, seventy-fifth percentile 9.2, 11.8). The baseline median plasma tHcy level was 10.0 mumol/L (twenty-fifth, seventy-fifth percentile 8.1, 11.0), and treatment with folic acid/vitamin B(12) lowered the tHcy levels by 22%. At follow-up, we found 309 lesions with a significant decrease from baseline in the minimum lumen diameter of a mean of -0.16 +/- 0.4 mm and an increase in the diameter stenosis of 4.4 +/- 0.7%. Treatment with folic acid/vitamin B(12) or vitamin B(6) was not associated with a change in diameter stenosis or minimum lumen diameter. In a post hoc analysis, folic acid/vitamin B(12) treatment was significantly associated with rapid progression (odds ratio 1.84, 95% confidence interval 1.07 to 3.18). In conclusion, vitamin B treatment showed no beneficial effect on the angiographic progression of coronary artery disease, and the post hoc analyses suggested that folic acid/vitamin B(12) treatment might promote more rapid progression.

Download full-text

Full-text

Available from: Per M Ueland, Aug 27, 2015
0 Followers
 · 
128 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Hintergrund Hyperhomocysteinämie, die bei mehr als 60 % der Patienten/innen vorliegt, zählt zu den unabhängigen Risikofaktoren bei retinalen Arterienverschlüssen. Methode 120 Patienten/innen mit RAO wurden bezüglich Vorliegen einer Hyperhomocysteinämie ausgewertet und die aktuelle Literatur zur Homocysteinsenkung diskutiert. Resultate Eine Hyperhomocysteinämie von > 10 µmol/l lag bei 82,5 % und eine Hyperhomocysteinämie von > 15 µmol/l bei 44,3 % unserer Patienten/innen vor. Der mittlere Homocysteinplasmaspiegel war 15,5 µmol/l ± 6 µmol/l. Nebenbefundlich konnte bei 64,2 % eine arterielle Hypertonie, bei 55 % eine Hypercholesterinämie und bei 17,5 % ein Diabetes mellitus erhoben oder neu diagnostiziert werden. Schlussfolgerung Hyperhomocysteinämie zählt zu den häufigsten Comorbiditäten der retinalen arteriellen Verschlüsse, jedoch kann zum aktuellen Zeitpunkt eine Homocysteinsenkung bei Patienten/innen mit RAO bis zum Vorliegen von Studien, die einen Benefit zeigen, nicht routinemäßig empfohlen werden.
    Spektrum der Augenheilkunde 08/2013; 27(4). DOI:10.1007/s00717-013-0175-4 · 0.18 Impact Factor
  • Current Neurology and Neuroscience Reports 10/2010; 11(1):1-5. DOI:10.1007/s11910-010-0152-0 · 3.67 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Coronary artery ectasia (CAE) is characterized by an abnormal dilatation of the coronary arteries. The ratio of L-arginine/asymmetric dimethylarginine (ADMA) and homocysteine are important factors for endothelial function. In this study, we investigate the ratio of L-arginine/ADMA, homocysteine, and folic acid/vitamin B levels in patients with CAE. Forty patients diagnosed with CAE using coronary angiography were included in the study (24 male; mean age, 56 ± 11 years). The control group consisted of 30 patients who had normal coronary arteries as determined by coronary angiography (11 male; mean age, 54 ± 8 years). The ratio of L-arginine/ADMA and plasma homocysteine was measured using high-performance liquid chromatography. The L-arginine/ADMA ratio and L-arginine levels were significantly lower in the CAE group compared with the control group (110 ± 27 vs. 149 ± 77, P=0.02 and 157 ± 32 μmol/l vs. 187 ± 59 μmol/l, P=0.02, respectively). Plasma ADMA levels were similar in the two groups. Patients with CAE had higher plasma homocysteine levels (P=0.01). Plasma folic acid, vitamin B6, and vitamin B12 levels were similar between the two groups. This study shows that patients with CAE have a lower L-arginine/ADMA ratio and higher plasma homocysteine levels. These results show a potential relationship between endothelial dysfunction and CAE.
    Coronary artery disease 12/2010; 21(8):445-9. DOI:10.1097/MCA.0b013e32833fd22b · 1.30 Impact Factor
Show more